Dr. John Cush RheumNow
2 years 7 months ago
Excess Cardiovascular Risk in Gout
A UK population cohort study has shown that gout carries an increased risk for a wide variety of cardiovascular disorders.
https://t.co/ThDbAkI0VN https://t.co/uYz9Swu6sR
Dr. John Cush RheumNow
2 years 7 months ago
Can Biomarkers Improve Cardiovascular Risk Assessments in RA?
The TARGET (Treatments Against RA and Effect on FDG PET/CT) trial showed that different treatment strategies equally benefited arterial inflammation (by FDG-PET) in rheumatoid arthritis.
https://t.co/NTI57kTtAy https://t.co/idf4qTtKcw
Dr. John Cush RheumNow
2 years 7 months ago
It's a Sore Subject
Cindy Chiu, DO, presents her poster at RWCS 2024.
https://t.co/Bl7mAL4grR https://t.co/9rLglObu4V
Dr. John Cush RheumNow
2 years 7 months ago
Sinusitis Linked to 40% Heightened Risk of Rheumatic Disease
The common inflammatory condition sinusitis is linked to a 40% heightened risk of a subsequent diagnosis of rheumatic disease, finds research published in the open access journal RMD Open.
https://t.co/WApFsSzn1W https://t.co/jNv6MClCRk
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are these associations with infection, biomarkers and weather real or imaginary? Linked or luck? Causal or casual? You decide....
Dr. John Cush RheumNow
2 years 7 months ago
Join our experts, Drs Liebowitz and Mehta, as they provide insights on the differential diagnosis and management concepts in autoinflammatory diseases.
https://t.co/FJtWtaxXeG https://t.co/olcRoFZrBY
Dr. John Cush RheumNow
2 years 7 months ago
Metabolic signature for fibromyalgia? Study of 54 FM & 31 controls w/ Machine learning to identify 13 metabolic markers that predicted FM w/ 79% accuracy; levels of 5-hydroxyindole-3-acetic acid & glutamine correlated w/ fatigue. https://t.co/YAjffGVATG https://t.co/5UWNpDNioT
Dr. John Cush RheumNow
2 years 7 months ago
As of 11/23, FDA has approved 44 biosimilars to 14 different reference products. FDA systematic review on biosimilars found no differences in the risk of death, serious adverse events, or treatment discontinuations between the switch and no-switch arms.https://t.co/yVScZnP559 https://t.co/feswD1gJz9
Despite the availability of numerous advanced therapies for psoriatic arthritis (PsA), there remains a substantial burden and unmet need for improved therapies, according to a newly published Canadian study.
A multinational study of polyarteritis nodosa (PAN) through the international GLOBAL-PAN network shows PAN to be a complex, multisystem disorder with a high risk of relapse and low risk of death (11% at 10 years).
Dr. John Cush RheumNow
2 years 7 months ago
In 2023, the FDA approved 956 generic drugs and issued 1,493 complete response letters; an improvement on 2022’s 914 approvals and 1,775 complete response letters. https://t.co/XnpQLbxJCr https://t.co/zzf63G4s2R
Dr. John Cush RheumNow
2 years 7 months ago
IBD extraintestinal & joint manifestations - systematic review of 61 studies (13,806 pts) found 8% new joint findings during advanced therapy (no signif difference betw vedolizumab (9%) & ustekinumab (6%). https://t.co/drFAtBG4ZU https://t.co/N8ixHS64HD
